British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...

ViiV Healthcare, the HIV-focused joint venture majority owned by GSK , said on Monday it has expanded its licensing deal with ...

GSK PLC closed 16.09% below its 52-week high of £16.79, which the company achieved on September 9th.

GSK PLC closed 13.35% below its 52-week high of £16.79, which the company reached on September 9th.

FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.

GSK has applied to the US Food and Drug Administration (FDA) to extend use of its respiratory syncytial virus (RSV) vaccine Arexvy to adults under the age of 50 who are at increased risk of the ...

In the segment, while products like Nucala and Dovato are key top-line drivers, new long-acting HIV medicines, Cabenuva and ...

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...

"A regulatory decision by the FDA on this submission is expected in H1 2026. GSK is continuing to seek expanded indications for its RSV vaccine in other geographies including in the European Economic ...

Analysts believe that Gilead's new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say ...

In the latest twist in the ocean of Zantac-related litigation playing out across state courts, drugmakers have notched a key ...

Delaware's Supreme Court sides with drugmakers including GSK (GSK) and Pfizer (PFE), rejecting expert testimony linking ...